Key result
Enhanced-dose atorvastatin for STEMI patients undergoing emergency PCI improved cardiac and vagus nerve function and reduced the incidence of major adverse cardiac events compared to standard dose.
Why the study?
This study investigated the effect of statins on the efficacy and prognosis of STEMI patients after emergency PCI.
Does enhanced-dose atorvastatin improve cardiac function and reduce MACE in STEMI patients undergoing emergency PCI?
RCT (n=98)
No
Does enhanced-dose atorvastatin improve cardiac function and reduce MACE in STEMI patients undergoing emergency PCI?
Enhanced-dose atorvastatin loading before and immediately after emergency PCI for STEMI may improve cardiac and autonomic function and reduce short-term MACE.
May support enhanced atorvastatin dosing in STEMI post-PCI; hypothesis-generating and requires larger confirmatory trials.
Background: Acute ST-segment elevation myocardial infarction (STEMI) is a serious multiple acute cardiovascular disease. This study investigated the effect of statins on the efficacy and prognosis of STEMI patients after emergency PCI. Methods: From October 2019 to January 2021, 98 patients with STEMI in our hospital were selected and divided into study group and control group. The study group took atorvastatin 40 mg 2 hours before surgery, 40 mg/day after surgery, and 20 mg/day 1 week later. The control group received 20 mg of atorvastatin every night after admission. The cardiac output, left ventricular ejection fraction, blood flow classification, vagus nerve function, heart rate deceleration force and chemoreflex sensitivity were compared between the two groups, and recorded the incidence of adverse reactions before and after treatment and 3 months after treatment. The number of major adverse cardiac events (MACEs) was also recorded. Results: Before treatment, there were no differences in CO, CI, and LVEF between the study and control groups. After treatment, CO, CI, and LVEF in the study group were significantly higher than those in the control group. Before treatment, there was no significant difference in TIMI blood flow classification among the groups, and after treatment, the study group was better than the control group. DC and ChRS were significantly higher in the study group than in the control group. There was no difference in the incidence of adverse reactions between the study group and the control group. However, the incidence of MACE in the study group was lower than that in the control group. Conclusion: Enhanced-dose atorvastatin for STEMI patients improved PCI treatment effect, cardiac function, and vagus nerve function and reduced the incidence of adverse cardiac events. Thus, statins are safe and worth considering.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2022) conducted an RCT in ST-segment elevation myocardial infarction (STEMI) (n=98). Enhanced-dose atorvastatin vs. 20 mg of atorvastatin every night after admission was evaluated on Cardiac function, vagus nerve function, and major adverse cardiac events (MACE). Enhanced-dose atorvastatin for STEMI patients undergoing emergency PCI improved cardiac and vagus nerve function and reduced the incidence of major adverse cardiac events compared to standard dose.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: